
”Just disappointing.”
This is how Bo Jesper Hansen, biotech company Orphazyme’s deputy chairman, describes what looks to be a rejection of the company’s candidate, arimoclomol, from the CHMP, the expert committee for European Medicines Agency (EMA).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app